Kenneth Brayman

Dr. Kenneth Brayman


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2017 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Verified
Journal Article
Open access
PDF file
DBDaniel T. Bowers
Daniel T. Bowers
COClaire E. Olingy
Claire E. Olingy
PCPreeti Chhabra
Preeti Chhabra
LLLinda Langman
Linda Langman
PMParker H. Merrill
Parker H. Merrill
EBEdward A. Botchwey
Edward A. Botchwey
Macroencapsulation is a powerful approach to increase the efficiency of extrahepatic pancreatic islet transplant. FTY720, a small molecule that activates signaling through sphingosine‐1‐phosphate receptors, is immunomodulatory and pro‐angiogenic upon sustained delivery from biomaterials. While FTY720 (fingolimod, Gilenya) has been explored for organ transplantation, in the present work the effect of locally released FTY720 from novel nanofiber‐based macroencapsulation membranes is explored for islet transplantation. We screened islet viability during culture with FTY720 and various biodegradable polymers. Islet viability is significantly reduced by the addition of high doses (≥500 ng/mL) of soluble FTY720. Among the polymers screened, islets have the highest viability when cultured with poly(3‐hydroxybutyrate‐co‐3‐hydroxyvalerate) (PHBV). Therefore, PHBV was blended with polycaprolactone (PCL) for mechanical stability and electrospun into nanofibers. Islets had no detectable function ex vivo following 5 days or 12 h of subcutaneous implantation within our engineered device. Subsequently, we explored a preconditioning scheme in which islets are transplanted 2 weeks after FTY720‐loaded nanofibers are implanted. This allows FTY720 to orchestrate a local regenerative milieu while preventing premature transplantation into avascular sites that contain high concentrations of FTY720. These results provide a foundation and motivation for further investigation into the use of FTY720 in preconditioning sites for efficacious islet transplantation. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 555–568, 2018.

1 June 2004 in Transplantation Proceedings
Verified
Journal Article
Closed access
ZYZ Yang
Z Yang
MCM Chen
M Chen
SDShuli Deng
Shuli Deng
JEJ.D Ellett
J.D Ellett
RWR Wu
R Wu
Kenneth BraymanKenneth Brayman
Kenneth Brayman

27 November 2013 in Surgical Infections
Verified
Journal Article
Open access
LRLaura H. Rosenberger
Laura H. Rosenberger
JGJacob R. Gillen
Jacob R. Gillen
THTjasa Hranjec
Tjasa Hranjec
JSJayme B. Stokes
Jayme B. Stokes
Kenneth BraymanKenneth Brayman
Kenneth Brayman
Robert G SawyerRobert G Sawyer
Robert G Sawyer
Background: The Donor Risk Index (DRI) is used to predict graft survival following liver transplantation, but has not been used to predict post-operative infections in graft recipients. We hypothesized that lower-quality grafts would result in more frequent infectious complications. Methods: Using a prospectively collected infection data set, we matched liver transplant recipients (and the respective allograft DRI scores) with their specific post-transplant infectious complications. All transplant recipients were organized by DRI score and divided into groups with low-DRI and high-DRI scores. Results: We identified 378 liver transplants, with 189 recipients each in the low-DRI and high-DRI groups. The mean DRI scores for the low- and high-DRI-score groups were 1.14±0.01 and 1.74±0.02, respectively (p<0.0001 for the difference). The mean Model for End-Stage Liver Disease (MELD) scores were 26.25±0.53 and 24.76±0.55, respectively ( p =0.052), and the mean number of infectious complications per patient were 1.60±0.19 and 1.94±0.24, respectively (p=0.26). Logistic regression showed only length of hospital stay and a history of vascular disease as being associated independently with infection, with a trend toward significance for MELD score (p=0.13). Conclusion: We conclude that although DRI score predicts graft-liver survival, infectious complications depend more heavily on recipient factors.

21 February 2018 in Case Reports in Surgery
Verified
Journal Article
Open access
PDF file
RSR. Shahbazov
R. Shahbazov
MTM. Talanian
M. Talanian
JAJ. L. Alejo
J. L. Alejo
FAF. Azari
F. Azari
AAA. Agarwal
A. Agarwal
Kenneth BraymanKenneth Brayman
Kenneth Brayman
Introduction. Encapsulating peritoneal sclerosis (EPS) is a clinical syndrome of progressive fibrotic change in response to prolonged, repetitive, and typically severe insult to the peritoneal mesothelium, often occurring in the setting of peritoneal dialysis (PD). Clear guidelines for successful management remain elusive. We describe the successful surgical management of EPS in a 28-year-old male s/p deceased donor kidney transplant for end-stage renal disease (ESRD) secondary to focal segmental glomerulosclerosis (FSGS). This patient received PD for 7 years but changed to hemodialysis (HD) in the year of transplant due to consistent signs and symptoms of underdialysis. EPS was visualized at the time of transplant. Despite successful renal transplantation, EPS progressed to cause small bowel obstruction (SBO) requiring PEG-J placement for enteral nutrition and gastric decompression. The patient subsequently developed a chronic gastrocutaneous fistula necessitating chronic TPN and multiple admissions for pain crises and bowel obstruction. He was elected to undergo surgical intervention due to deteriorating quality of life and failure to thrive. Surgical management included an exploratory laparotomy with extensive lysis of adhesions (LOA), repair of gastrocutaneous fistula, and end ileostomy with Hartmann’s pouch. Postoperative imaging confirmed resolution of the SBO, and the patient was transitioned to NGT feeds and eventually only PO intake. He is continuing with PO nutrition, gaining weight, and free from dialysis.Conclusion. Surgical intervention with LOA and release of small intestine can be successful for definitive management of EPS in the proper setting. In cases such as this, where management with enteral nutrition fails secondary to ongoing obstructive episodes, surgical intervention can be pursued in the interest of preserving quality of life.

23 September 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
JLJane J. Long
Jane J. Long
JMJennifer D. Motter
Jennifer D. Motter
KJKyle R. Jackson
Kyle R. Jackson
JCJennifer Chen
Jennifer Chen
BOBabak J. Orandi
Babak J. Orandi
JGJacqueline M. Garonzik-Wang
Jacqueline M. Garonzik-Wang
Older compatible living donor kidney transplant (CLDKT) recipients have higher mortality and death-censored graft failure (DCGF) compared to younger recipients. These risks may be amplified in older incompatible living donor kidney transplant (ILDKT) recipients who undergo desensitization and intense immunosuppression. In a 25-center cohort of ILDKT recipients transplanted between September 24, 1997, and December 15, 2016, we compared mortality, DCGF, delayed graft function (DGF), acute rejection (AR), and length of stay (LOS) between 234 older (age >= 60 years) and 1172 younger (age 18-59 years) recipients. To investigate whether the impact of age was different for ILDKT recipients compared to 17 542 CLDKT recipients, we used an interaction term to determine whether the relationship between posttransplant outcomes and transplant type (ILDKT vs CLDKT) was modified by age. Overall, older recipients had higher mortality (hazard ratio: (1.63)2.07(2.65), P < .001), lower DCGF (hazard ratio: (0.36)0.53(0.77), P = .001), and AR (odds ratio: (0.39)0.54(0.74), P < .001), and similar DGF (odds ratio: (0.46)1.03(2.33), P = .9) and LOS (incidence rate ratio: (0.88)0.98(1.10), P = 0.8) compared to younger recipients. The impact of age on mortality (interaction P = .052), DCGF (interaction P = .7), AR interaction P = .2), DGF (interaction P = .9), and LOS (interaction P = .5) were similar in ILDKT and CLDKT recipients. Age alone should not preclude eligibility for ILDKT.

26 February 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
BMBarbara J. Mann
Barbara J. Mann
PCPreeti Chhabra
Preeti Chhabra
MMMingyang Ma
Mingyang Ma
SBSavannah G. Brovero
Savannah G. Brovero
MJMarieke K. Jones
Marieke K. Jones
Kenneth BraymanKenneth Brayman
Kenneth Brayman
Effective and available therapies for the treatment of COVID-19 disease are limited. Apadenoson is a highly potent selective anti-inflammatory adenosine A 2A receptor (A 2A R) agonist and potential treatment option for COVID-19 patients. Apadenoson, when administered after infection with SARS CoV-2, was found to decrease weight loss, improve clinical symptoms, reduce levels of a several proinflammatory cytokines and chemokines in bronchial lavage (BAL) fluid, and promote increased survival in K18hACE2 transgenic mice. Of note, administering apadenoson after, but not prior to Covid-19 infection, caused a rapid decrease in lung viral burden. The work presented provides the foundation for further examination of these drugs as a therapy option for COVID-19. Summary: Apadenoson therapy improves COVID-19 outcome